Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, Michael Andrew Postow, Naiyer A. Rizvi, Alexander M. Lesokhin, Neil Howard Segal, Charlotte Eielson Ariyan, RuthAnn Gordon, Matthew M. Burke, Anne Barman Caldwell, Stephanie Anne Kronenberg, Blessing Agunwamba, Xiaoling Zhang, Israel Lowy, Hector David Inzunza, William F. Feely, Christine E. Horak, Quan Hong, Alan J. Korman, Jon M. Wigginton, Ashok Kumar Gupta, Mario Sznol
New England Journal of Medicine · 2013 · 4,287 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Wolchok, J. D., Kluger, H. M., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R., Reed, K., Burke, M. M., Caldwell, A. B., Kronenberg, S. A., Agunwamba, B., Zhang, X., Lowy, I., Inzunza, H. D., Feely, W. F., Horak, C. E., … Sznol, M. (2013). Nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine, 369(2), 122–133. https://doi.org/10.1056/nejmoa1302369
In text: (Wolchok et al., 2013)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis of their distinct immunologic mechanisms of action and supportive preclinical data, we conducted a phase 1 trial of nivolumab combined with ipilimumab in patients with advanced melanoma. METHODS: We administered intravenous doses of nivolumab and ipilimumab in patients every 3 weeks for 4 doses, followed by nivolumab alone every 3 weeks for 4 doses (concurrent regimen). The combined treatment was subsequently administered every 12 weeks for up to 8 doses. In a sequenced regimen, patients previously treated with ipilimumab received nivolumab every 2 weeks for up to 48 doses. RESULTS: A total of 53 patients received concurrent therapy with nivolumab and ipilimumab, and 33 received sequenced treatment. The objective-response rate (according to modified World Health Organization criteria) for all patients in the concurrent-regimen group was 40%. Evidence of clinical activity (conventional, unconfirmed, or immune-related response or stable disease for ≥24 weeks) was observed in 65% of patients. At the maximum doses that were associated with an acceptable level of adverse events (nivolumab at a dose of 1 mg per kilogram of body weight and ipilimumab at a dose of 3 mg per kilogram), 53% of patients had an objective response, all with tumor reduction of 80% or more. Grade 3 or 4 adverse events related to therapy occurred in 53% of patients in the concurrent-regimen group but were qualitatively similar to previous experience with monotherapy and were generally reversible. Among patients in the sequenced-regimen group, 18% had grade 3 or 4 adverse events related to therapy and the objective-response rate was 20%. CONCLUSIONS: Concurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; ClinicalTrials.gov number, NCT01024231.).
Related papers
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer2016
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review2017
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016
Metadata from OpenAlex (CC0). Citations are generated from the published record.